Accuray Wins Chinese Nod for Precision Treatment Planning System, Boosting Regional Expansion
U.S. medical device company Accuray Inc. (NASDAQ: ARAY) has announced that it has received market...
Company
Pfizer Forges Partnership with Flagship Pioneering for Novel Obesity Treatments
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has initiated a strategic partnership with Flagship Pioneering, a...
Eli Lilly’s Tirzepatide Hits Primary Endpoint in MASH Trial, Outperforming Placebo
Eli Lilly and Company (NYSE: LLY), a global healthcare conglomerate, has announced positive outcomes from...
AbbVie-Calico Partnership Advances with FDA Approval for Fosigotifator Trial in Rare Brain Disorder
The US Food and Drug Administration (FDA) has welcomed an experimental therapy, fosigotifator, developed by...
Junshi Biosciences’ Toripalimab Scores New Indication for First-Line ES-SCLC Treatment in China
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced an expansion of indications...
Kyowa Kirin’s Evocalcet Wins NMPA Nod for Chronic Kidney Disease Treatment
Kyowa Kirin Co. (TYO: 4151), a Japanese pharmaceutical firm, has secured marketing approval from China’s...
Sperogenix Launches Early Access Program for DMD Therapy Agamgree in Hainan
Switzerland-based Santhera Pharmaceuticals (SWX: SANN) has announced that its Chinese partner Sperogenix Therapeutics has initiated...
Zymeworks and BeiGene Submit BLA in China for Zanidatamab as Second-Line HER2-Positive BTC Treatment”
Zymeworks Inc. (NASDAQ: ZYME), a Canadian biotech company, in partnership with BeiGene (NASDAQ: BGNE; HKG:...
Zai Lab’s Global R&D Leadership Transition: Dr. Harald Reinhart to Retire, Dr. Rafael Amado Expands Role
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a leading biopharmaceutical company based in China, has...
FDA Committee Backs Eli Lilly’s Donanemab for Early Symptomatic Alzheimer’s Disease
This week, a US Food and Drug Administration (FDA) advisory committee endorsed the safety and...
Luye Pharma’s Paliperidone Palmitate Injection Wins NMPA Nod for Schizophrenia Treatment
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced that...
Junshi Biosciences’ Toripalimab-Bevacizumab Combo Meets Primary Endpoints in HCC Phase III Trial
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has declared a significant milestone with...
SinoMab BioScience’s SM17 Atopic Dermatitis Drug Reaches First Patient Milestone in Phase Ib Trial
SinoMab BioScience Ltd (HKG: 3681), a biotech firm based in Hong Kong, has announced the...
CGP’s GPN00884 Myopia Drug Enters Phase I Clinical Trial with First Patient Dosed
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced the commencement of...
Sino Biopharmaceutical’s KRAS Inhibitor Garsorasib Earns Breakthrough Designation in China
Sino Biopharmaceutical Ltd (HKG: 1177), a prominent biopharmaceutical company in China, has announced that its...
Sansure Biotech’s Tuberculosis Detection Kit Gains CE IVDR Certification for EU Market
Sansure Biotech Inc. (SHA: 688289), a leading molecular diagnostics company based in China, has announced...
Ascentage Pharma Gets Green Light for Global Phase III Trial of Olverembatinib in SDH-Deficient GIST
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced that it has...
Kyowa Kirin to Invest $530 Million in US Biologics Factory for Rare Disease Therapies
Japanese pharmaceutical company Kyowa Kirin (TYO: 4151) has unveiled plans for a substantial investment of...
Johnson & Johnson to Acquire Biotechnology Firm Yellow Jersey for $1.25 Billion
Johnson & Johnson (J&J; NYSE: JNJ), a global healthcare conglomerate, has entered into a definitive...
Bayer’s HER2 Targeting Drug BAY 2927088 Earns Breakthrough Designation in China
The Center for Drug Evaluation (CDE) in China has granted Breakthrough Therapy Designation (BTD) to...